PRESS RELEASE
News
-
-
PRESS RELEASE
THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)
THX Pharma and BBDF announce European patent grant for Batten-1 treatment of juvenile Batten disease, ensuring long-term exclusivity through 2041 -
-
-
PRESS RELEASE
THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3)
THX Pharma, BBDF, and Biocodex submit regulatory applications for Phase 3 trial of Batten-1, a treatment for juvenile Batten disease. Trial aims to evaluate efficacy in pediatric patients -
PRESS RELEASE
THX Pharma, BBDF et Biocodex annoncent le dépôt des demandes d'autorisation de l'essai clinique de phase 3 de Batten-1 dans la maladie de Batten juvénile (CLN3)
THX Pharma, accompagné de ses partenaires Beyond Batten Disease Foundation (BBDF) et Biocodex, dépose les demandes d'autorisation réglementaire pour l'essai clinique de phase 3 de Batten-1, un traitement pour la maladie de Batten juvénile (CLN3) -
-
-
-
